Jump to main content
Jump to site search

Issue 6, 2012
Previous Article Next Article

Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation

Author affiliations

Abstract

The short-chain fatty acid butyrate is classically referred to as an inhibitor of histone deacetylases (HDACi), however evidence from direct assays is both sparse and contradictory. This paper assesses the strength of the historical evidence, potential gaps, inadequacies and simplifications in the butyrate-as-HDACi hypothesis. An alternate model to explain the action of butyrate is proposed wherein butyrate acts as a product inhibitor of deacetylation. The model makes testable predictions which may enable future determination of the mode of action of this and other SCFAs.

Graphical abstract: Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 24 Jan 2012, accepted on 23 Feb 2012 and first published on 28 Feb 2012


Article type: Opinion
DOI: 10.1039/C2MB25028D
Citation: Mol. BioSyst., 2012,8, 1609-1612
  •   Request permissions

    Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation

    B. M. Corfe, Mol. BioSyst., 2012, 8, 1609
    DOI: 10.1039/C2MB25028D

Search articles by author